Loading stock data…
RVMD
$149.55+1.06 (+0.71%)
After Hours$149.56+0.01 (+0.01%)· Last close Jun 9
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revolution Medicines, Inc. in the Healthcare sector is trading at $148.57. Wall Street consensus targets $186.33 (21 analysts), implying a +25.4% move over the next 12 months. The stock is currently near its 52-week high of $166.50, remaining 63.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$149.55
Potential Downside
0%
Whystock Fair Value$149.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$186.33+24.6%
Range$151.00 – $263.00
Fundamentals
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as m...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-91.45%
Volume
Today's trading volume
2.76M
Recent News
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Tango Therapeutics stock surges on pancreatic cancer trial data
A combination of vopimetostat and Revolution Medicines' daraxonrasib produced a 92% response rate in patients with advanced pancreatic cancer
Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment
Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’
Tango Skyrockets On Eye-Popping Pancreatic Cancer Results
Tango Therapeutics stock skyrocketed Monday after the biotech company added to the Revolution Medicines' results in pancreatic cancer.
🔎 Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data
Shares of Tango Therapeutics surged 53% Monday after the biotech announced that combining its experimental drug vopimetostat with Revolution Medicines’ daraxonrasib shrank tumors in 11 of 12 pancreatic cancer patients in an early stage trial.